Pulmonology

Stallergenes Greer Publishes in the Lancet Regional Health-Europe Landmark EfficAPSI Real-world Study Confirming Significant Benefit of Its Liquid Sublingual AIT on the Onset and Progression of Allergic Asthma

Retrieved on: 
Thursday, May 2, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Hospitals, Other Health, Public, Society, Risk, GINA, MD, Doctor of Philosophy, Global Initiative for Asthma, Allergen, AIT, Patient, Allergic rhinitis, Pulmonology, Asthma, Quality of life, Pharmaceutical industry

The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.

Key Points: 
  • The primary objective of the study was the evaluation of the real-world impact of Stallergenes Greer SLIT-liquid on the prevention of asthma onset or worsening in patients with allergic rhinitis.
  • “Exploring the impact of allergen immunotherapy on asthma onset and progression is crucial, and we're committed to filling those gaps.
  • Through this real-world EfficAPSI study, Stallergenes Greer is honoured to contribute valuable scientific evidence and insights to allergy treatment.
  • By demonstrating the benefit on the onset and worsening of asthma, Stallergenes Greer SLIT-liquid treatments confirm their impact in terms of public health.

bioAffinity Technologies News Update

Retrieved on: 
Thursday, May 2, 2024
Research, Medical Devices, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Physician, Nursing care plan, ATS, Chronic obstructive pulmonary disease, Lung cancer, Bronchoalveolar lavage, Conference, Baxter International, BIAF, Lung, Patient, Pulmonology, Marketing, Empathy, BAL, American Thoracic Society, Fluid, COPD, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.
  • Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology Laboratory Services, to order CyPath® Lung for their patients.
  • bioAffinity Technologies’ National Sales Director Dallas Coleman announced that Jackie Kennedy has joined the Company as Pulmonary Sales Executive for CyPath® Lung in the San Antonio/Austin market.
  • “Patients have told us how much they appreciate having a Patient Coach who can walk them through the collection process,” bioAffinity Technologies President and CEO Maria Zannes said.

26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic

Retrieved on: 
Wednesday, March 27, 2024
Conference, Growth, Sarcoidosis, Face, Learning, Volunteering, Disease, Caregiver, Patient, Knowledge, Pulmonology, Hospital, Research, FSR, Division, Hospital for Special Surgery, Health, Nursing

CHICAGO, March 27, 2024 (GLOBE NEWSWIRE) -- 26 Patient Volunteer Leaders representing 16 states and 17 hospitals joined the Foundation for Sarcoidosis Research (FSR) at the inaugural FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic.

Key Points: 
  • CHICAGO, March 27, 2024 (GLOBE NEWSWIRE) -- 26 Patient Volunteer Leaders representing 16 states and 17 hospitals joined the Foundation for Sarcoidosis Research (FSR) at the inaugural FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic.
  • "We are immensely proud of the success of the FSR-GSCA Volunteer Patient Leadership Training Conference," said Mary McGowan, Chief Executive Officer of FSR.
  • The success of the FSR-GSCA Volunteer Patient Leadership Training would not have been possible without the generous support of Cleveland Clinic.
  • For more information about the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance, visit www.stopsarcoidosis.org.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

EQS-News: AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Retrieved on: 
Wednesday, March 13, 2024
Bronchiectasis, American Journal, Pulmonology, Asthma, AAT, European Respiratory Society, FERS, GOLD, Patient, Chronic obstructive pulmonary disease, Global Initiative, German Respiratory Society, Critical Care Medicine (journal), COPD, Pharmaceutical industry

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Key Points: 
  • AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
    The issuer is solely responsible for the content of this announcement.
  • AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
    Leading pulmonology expert contributes profound clinical experience in inflammatory lung diseases such as bronchiectasis, COPD, asthma, and ARDS to AATec Medical.
  • Munich, Germany – 29.02.2024 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform technology based on recombinant alpha-1 antitrypsin (AAT), today announced the appointment of Prof. Dr. Claus Franz Vogelmeier, Professor of Medicine and Head of the Department of Pulmonary Medicine at Philipps-University in Marburg, Germany to its Scientific Advisory Board.
  • Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: “We are very pleased to welcome Professor Vogelmeier to our Scientific Advisory Board.

Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Chemistry, Investment, GM, Pulmonology, BLA, APAP, Patient, Disease, Chair, Inc., Cryptocurrency

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update.
  • Research and development expenses for the fourth quarter of 2023 and 2022 were $12.7 million and $7.6 million, respectively.
  • General and administrative expenses for the fourth quarter of 2023 and 2022 were $4.9 million and $3.2 million, respectively.
  • As of December 31, 2023, the Company had cash, cash equivalents and short-term investments of $162.3 million.

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

Retrieved on: 
Tuesday, March 5, 2024
Research, Medical Devices, Hospitals, Genetics, Clinical Trials, Biotechnology, Health, Science, Oncology, BIAF, Lung cancer, Pulmonology, Disease, Lung, Growth, Diagnosis, Risk, Medical imaging

CyPath® Lung is a noninvasive test to detect early-stage lung cancer.

Key Points: 
  • CyPath® Lung is a noninvasive test to detect early-stage lung cancer.
  • bioAffinity Technologies is on target to meet its sales forecast for the previously announced limited test market launch in Texas designed to refine future positioning and strategic insight for CyPath® Lung in preparation for expanding to the national market.
  • bioAffinity Technologies' commitment to noninvasive cancer detection is poised to reshape the landscape of lung health management by increasing early detection and treatment.
  • bioAffinity Technologies will release financial results for the fourth quarter and full year ended December 31, 2023, on April 1, 2024.

Laura Davis Joins VisionAir Solutions as Executive Director of Education

Retrieved on: 
Wednesday, February 14, 2024
Physician, FDA, Bachelor of Science, University of Michigan, Pulmonology, Business development, Lead, Dynasplint Systems, Stent, Patient, Western Michigan University, Anatomy, Disease, Software

CLEVELAND, Feb. 14, 2024 /PRNewswire/ -- VisionAir Solutions, a Cleveland, Ohio-based company that creates patient-specific airway stents announced that Laura Davis has joined its team as Executive Director of Education.

Key Points: 
  • Business development and sales leader Laura Davis joins VisionAir Solutions team as Executive Director of Education.
  • CLEVELAND, Feb. 14, 2024 /PRNewswire/ -- VisionAir Solutions, a Cleveland, Ohio-based company that creates patient-specific airway stents announced that Laura Davis has joined its team as Executive Director of Education.
  • Business development and sales leader Laura Davis joins VisionAir Solutions team as Executive Director of Education.
  • Laura joins VisionAir from an impressive background as a sales leader and education consultant.

Thirona receives FDA 510(k) Clearance for LungQ v3.0.0 Software to Power AI Analysis of Chest CT Images

Retrieved on: 
Monday, January 22, 2024
Technology, FDA, Hospitals, Clinical Trials, Health Technology, Software, Health, Pharmaceutical, Artificial Intelligence, Artificial intelligence, Patient, Hospital, Food and Drug Administration, Documentation, Map, Lung cancer, Pulmonology, COPD, Food, Fissure, Lung, Publication, Diagnosis, Physician

LungQ 3.0.0 is one of the only FDA-cleared solutions that is capable of using AI to automatically segment the pulmonary segments and subsegments found in the internal anatomy of the lung.

Key Points: 
  • LungQ 3.0.0 is one of the only FDA-cleared solutions that is capable of using AI to automatically segment the pulmonary segments and subsegments found in the internal anatomy of the lung.
  • Rita Priori, CTO at Thirona: “Our AI-based image analysis software LungQ is already used by interventional pulmonologist in Europe and Australia, aiding clinicians through procedures like bronchoscopic lung volume reduction and other interventions.
  • The FDA 510(k) cleared LungQ opens tremendous new opportunities for planning and performing localized treatments with maximum precision and accuracy.
  • To learn more about the LungQ software, please visit our website.